---
title: "Charles River Laboratories International Inc. Stock Underperforms Thursday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286470256.md"
description: "Charles River Laboratories International Inc. (CRL) shares fell 2.29% to $159.12 on Thursday, marking the second consecutive day of losses. This decline occurred despite a positive trading session for the overall market, with the S&P 500 and Dow Jones rising. CRL's stock is currently 30.48% below its 52-week high of $228.88. In comparison, competitors Labcorp Holdings, Alnylam Pharmaceuticals, and Bio-Techne showed mixed performance. Trading volume was below the 50-day average."
datetime: "2026-05-14T21:17:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286470256.md)
  - [en](https://longbridge.com/en/news/286470256.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286470256.md)
---

# Charles River Laboratories International Inc. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Charles River Laboratories International Inc. (CRL) slid 2.29% to $159.12 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.77% to 7,501.24 and the Dow Jones Industrial Average rising 0.75% to 50,063.46.

This was the stock's second consecutive day of losses.

Charles River Laboratories International Inc. closed 30.48% short of its 52-week high of $228.88, which the company achieved on January 13th.

The stock underperformed when compared to some of its competitors Thursday, as Labcorp Holdings Inc. (LH) fell 0.16% to $254.02, Alnylam Pharmaceuticals Inc. (ALNY) rose 0.68% to $293.45, and Bio-Techne Corp. (TECH) fell 0.33% to $44.74.

Trading volume (829,093) remained 31,977 below its 50-day average volume of 861,070.

Data source: Dow Jones Market Data, FactSet. Data compiled May 14, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-14-26 1717ET

### Related Stocks

- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LH.US](https://longbridge.com/en/quote/LH.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)

## Related News & Research

- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)
- [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)